Close

Institute for Next Generation Healthcare
Icahn School of Medicine at Mount Sinai

770 Lexington Avenue, 15th Floor
New York, NY 10065
Tel: 212-731-7065
Email:INGH@mssm.edu

Thank you. Your message has been sent, we will get back to you shortly.

More

OUR CORE PREMISE

To improve health, we must close the gap between what we know and what we do.

role icon Created with Sketch.

Our Role

INGH is a working prototype for the future of healthcare that connects a growing community of leading scientists, medical experts, and entrepreneurs with patients to pull the future forward by demonstrating and experiencing tomorrow’s healthcare now.

Our Story

INGH is a team of innovators who have come together to demonstrate next generation healthcare through groundbreaking integration of research, technology and practice. We offer an inspirational ecosystem for healthcare professionals, patients, scientists and entrepreneurs determined to close the gap between health and care at a time when the failures of the current healthcare system call for an innovation movement to bring transformational change.

our approach icon Created with Sketch.

Our Approach

We are shaping the future of healthcare by incorporating scientific discovery, new partnerships and technological innovation to drive new models for patient care. By capturing, integrating and analyzing data, we are making possible a new level of understanding and practice, offering a radical alternative to the way we prevent, treat and manage illness.

Our Centers
Research Highlights

Building New Views of Alzheimer’s Disease

By mid-century, a new diagnosis of Alzheimer’s Disease (AD) will occur every 33 seconds, and costs are expected to exceed $1 trillion annually. Yet, despite the dire public health implications of this, AD remains the only top-10 cause of mortality in the United States, without any disease modifying treatments available. Our work at INGH includes a major focus on developing and applying integrative approaches to multiscale genomics data for the goal of improving therapeutic options for patients with neurodegenerative diseases.

FIND OUT MORE

Mulitscale Genomics of Acne

Acne is a powerful model for understanding interactions between our bodies, our microbiome, and our environment. The Icahn School of Medicine at Mount Sinai embarked on one of the largest acne studies to date to establish a multiscale biological network for acne, integrating patient DNA sequence data, gene expression profiling and microbial metagenomic data to capture the key aspects driving the pathology.

FIND OUT MORE

LymeMIND

Over the past decade, Lyme disease has increasingly become a health concern and is exacerbated by challenges in a timely and accurate diagnosis, as well as effective treatments and prevention. The Institute for Next Generation Healthcare at Mount Sinai launched an ambitious project called LymeMIND, which plans to collect all existing molecular and clinical data into a unified model that can be used to better understand and treat Lyme disease.

FIND OUT MORE

Over the past decade, Lyme disease has increasingly become a health concern and is exacerbated by challenges in a timely and accurate diagnosis, as well as effective treatments and prevention. The Institute for Next Generation Healthcare at Mount Sinai launched an ambitious project called LymeMIND, which plans to collect all existing molecular and clinical data into a unified model that can be used to better understand and treat Lyme disease.

Acne is a powerful model for understanding interactions between our bodies, our microbiome, and our environment. The Icahn School of Medicine at Mount Sinai embarked on one of the largest acne studies to date to establish a multiscale biological network for acne, integrating patient DNA sequence data, gene expression profiling and microbial metagenomic data to capture the key aspects driving the pathology.

By mid-century, a new diagnosis of Alzheimer’s Disease (AD) will occur every 33 seconds, and costs are expected to exceed $1 trillion annually. Yet, despite the dire public health implications of this, AD remains the only top-10 cause of mortality in the United States, without any disease modifying treatments available. Our work at INGH includes a major focus on developing and applying integrative approaches to multiscale genomics data for the goal of improving therapeutic options for patients with neurodegenerative diseases.